The EU Court of Justice dismisses all appeals brought by a Danish pharmaceutical company and five generic manufacturers against the judgments of the General Court and upholds a decision of the Commission on patent settlement agreements between the companies (Lundbeck)

On 25 March 2021, the CJEU dismissed all the appeals brought by Danish pharmaceutical company H. Lundbeck A/S and five generic manufacturers against the judgments of the GCEU, thus upholding a decision of the EC on patent settlement agreements between Lundbeck and five generic manufacturers (Case C-586/16 P, Sun Pharmaceutical Industries and Ranbaxy (UK) v Commission, EU:C:2021:241; Case C-588/16 P, Generics (UK) v Commission, EU:C:2021:242; Case C-591/16 P, Lundbeck v Commission, EU:C:2020:428; Case C-601/16 P, Arrow Group and Arrow Generics v Commission, EU:C:2021:244; Case C-611/16 P, Xellia Pharmaceuticals and Alpharma v Commission, EU:C:2021:245; and Case C-614/16 P, Merck v Commission, EU:C:2021:246). The judgment is significant as regards the interpretation and application of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • McDermott Will & Emery (Brussels)
  • McDermott Will & Emery (Paris)
  • McDermott Will & Emery (Paris)
  • McDermott Will & Emery (Brussels)
  • McDermott Will & Emery (Brussels)
  • McDermott Will & Emery (Washington)
  • McDermott Will & Emery (Dusseldorf)
  • McDermott Will & Emery (Brussels)

Quotation

Philip Bentley, Jacques Buhart, Frédéric Pradelles, Hendrik Viaene, David Henry, Mary Hecht, Max Küttner, Karolien Van der Putten, The EU Court of Justice dismisses all appeals brought by a Danish pharmaceutical company and five generic manufacturers against the judgments of the General Court and upholds a decision of the Commission on patent settlement agreements between the companies (Lundbeck), 25 March 2021, e-Competitions March 2021, Art. N° 105334

Visites 98

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues